(NASDAQ: MNKD) Mannkind's forecast annual revenue growth rate of 22.16% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.47%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.4%.
Mannkind's revenue in 2026 is $313,787,000.On average, 11 Wall Street analysts forecast MNKD's revenue for 2026 to be $133,071,976,974, with the lowest MNKD revenue forecast at $99,757,922,188, and the highest MNKD revenue forecast at $158,408,345,859. On average, 11 Wall Street analysts forecast MNKD's revenue for 2027 to be $151,579,102,810, with the lowest MNKD revenue forecast at $111,343,683,891, and the highest MNKD revenue forecast at $195,873,990,844.
In 2028, MNKD is forecast to generate $177,412,925,551 in revenue, with the lowest revenue forecast at $131,794,564,605 and the highest revenue forecast at $223,117,266,175.